Inhalon Biopharma, Inc.

Inhalon Biopharma, Inc. is a clinical-stage biotechnology company based in Carrboro, North Carolina, in the United States. The company is developing a proprietary inhaled drug platform for the treatment of acute respiratory infections, including respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza, and SARS-CoV-2. Its stated goal is to provide superior effectiveness and at-home convenience through inhaled antibody treatments that could enable a simplified "test-to-treat" model as a new standard of respiratory care. Inhalon was founded in 2018 by Sam Lai, Ph.D. The company's approach focuses on treating active infection directly in the lung, addressing what it describes as a massive unmet need because preventative vaccine therapies for acute respiratory infections do not fully protect people from infection. Its pipeline includes programs such as IN-006, an inhaled "muco-trapping" antibody for COVID-19; IN-002, a potential treatment for RSV; and IN-007, an inhaled ACE2-targeting therapeutic for SARS-CoV-2. The company has received support from a range of funders and agencies. In 2019 it received $500,000 from The Thiel Foundation through Breakout Labs and appointed John Whelan as Chief Executive Officer. In 2020 it raised $3.1 million in a Series Seed led by Life Science Angels. In 2021 it was awarded a $7 million grant from the U.S. Army Medical Research & Development Command (USAMRDC) to study IN-006, and it dosed the first patient in a Phase 1 study of inhaled IN-006. In 2022 it completed that Phase 1 study, raised $5 million in a Series A led by JSR Life Sciences and Life Science Angels, and received additional grants including $2 million from the National Institutes of Health (NIH) for IN-002 and $1.7 million from the North Carolina Collaboratory at the University of North Carolina at Chapel Hill for IN-007. In 2023 it dosed the first patient in a Phase 1b study of inhaled IN-006 and was awarded $1 million from the NIH to support IN-002 for RSV. As a private, clinical-stage company, Inhalon Biopharma is focused on advancing its inhaled antibody pipeline through clinical development. Its platform is designed to treat respiratory infections at the site of infection in the lungs, with the aim of improving outcomes and enabling convenient at-home care.

Inhalon Biopharma was founded in 2018 by Sam Lai, Ph.D. The company is based in Carrboro, North Carolina, and is a clinical-stage biotechnology company developing inhaled antibody treatments for acute respiratory infections. In 2019, Inhalon received $500,000 from The Thiel Foundation through Breakout Labs and appointed John Whelan as Chief Executive Officer. In 2020, the company raised $3.1 million in a Series Seed led by Life Science Angels. In 2021, Inhalon was awarded a $7 million grant from the U.S. Army Medical Research & Development Command (USAMRDC) to study IN-006, an inhaled "muco-trapping" antibody for the treatment of COVID-19. That year it also dosed the first patient in a Phase 1 study of inhaled IN-006. In 2022, the company completed the Phase 1 study of inhaled IN-006 and raised $5 million in a Series A led by JSR Life Sciences and Life Science Angels. It was awarded a $2 million grant from the National Institutes of Health (NIH) for IND-enabling development of inhaled IN-002, a potential treatment for respiratory syncytial virus (RSV). It released data for the Phase 1 inhaled IN-006 study on medRxiv and was awarded a $1.7 million grant from the North Carolina Collaboratory at the University of North Carolina at Chapel Hill to develop IN-007, an inhaled ACE2-targeting therapeutic for SARS-CoV-2. In 2023, Inhalon dosed the first patient in a Phase 1b study of inhaled IN-006 and was awarded $1 million from the NIH to support IN-002 for RSV. The company continues to advance its pipeline of inhaled antibody treatments for RSV, influenza, human metapneumovirus, and SARS-CoV-2.

• 2023

  Dosed first patient in Phase 1b study of inhaled IN-006; awarded $1 million from NIH to support IN-002 for RSV.

• 2022

  Completed Phase 1 study of inhaled IN-006; raised $5 million in Series A led by JSR Life Sciences and Life Science Angels; awarded $2 million NIH grant for IN-002; released Phase 1 IN-006 data on medRxiv; awarded $1.7 million grant from North Carolina Collaboratory for IN-007.

• 2021

  Awarded $7 million grant from USAMRDC to study IN-006; dosed first patient in Phase 1 study of inhaled IN-006.

• 2020

  Raised $3.1 million in Series Seed led by Life Science Angels.

• 2019

  Received $500,000 from The Thiel Foundation through Breakout Labs; appointed John Whelan as Chief Executive Officer.

• 2018

  Inhalon Biopharma founded by Sam Lai, Ph.D.

Clinical-stage biotechnology company developing inhaled antibody treatments to enable a simplified "test-to-treat" model as a new standard of respiratory care.

• IN-006

  Inhaled "muco-trapping" antibody for the treatment of COVID-19.

• IN-002

  Inhaled antibody in development as a potential treatment for respiratory syncytial virus (RSV).

• IN-007

  Inhaled ACE2-targeting therapeutic for SARS-CoV-2.

1. 1Inhalon Biopharma - Treating Respiratory Infectionsinhalon.com
2. 2About | Inhalon Biopharmainhalon.com
3. 3Inhalon Biopharma, Inc. (United States) - Wikidatawikidata.org